MA38591A1 - 6-Bridged Heteroaryldihydropyrimidines for the Treatment and Prophylaxis of Hepatitis B Virus Infection - Google Patents

6-Bridged Heteroaryldihydropyrimidines for the Treatment and Prophylaxis of Hepatitis B Virus Infection

Info

Publication number
MA38591A1
MA38591A1 MA38591A MA38591A MA38591A1 MA 38591 A1 MA38591 A1 MA 38591A1 MA 38591 A MA38591 A MA 38591A MA 38591 A MA38591 A MA 38591A MA 38591 A1 MA38591 A1 MA 38591A1
Authority
MA
Morocco
Prior art keywords
prophylaxis
hepatitis
treatment
virus infection
heteroaryldihydropyrimidines
Prior art date
Application number
MA38591A
Other languages
French (fr)
Inventor
Mingwei Zhou
Lei Guo
taishan Hu
Yimin Hu
Xianfeng Lin
Haixia Liu
Hong Shen
Guolong Wu
Wei Zhu
Buelent Kocer
Buyu Kou
Gangqin Li
Houguang Shi
Zhisen Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority claimed from PCT/EP2014/060034 external-priority patent/WO2014184328A1/en
Publication of MA38591A1 publication Critical patent/MA38591A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne de nouveaux composés de formule générale : dans laquelle r1, r2, r3 et r4 sont tels que définis dans la description et dans les revendications, ainsi que leurs sels, isomères tautomères ou énantiomères ou diastéréoisomères pharmaceutiquement acceptables. L'invention concerne également des compositions comprenant les composés et des méthodes d'utilisation des composés pour le traitement ou la prophylaxie d'une infection par le virus de l'hépatite b.The present invention relates to novel compounds of the general formula: wherein r1, r2, r3 and r4 are as defined in the specification and claims, and their pharmaceutically acceptable salts, tautomeric or enantiomeric or diastereoisomeric isomers. The invention also provides compositions comprising the compounds and methods of using the compounds for the treatment or prophylaxis of hepatitis b virus infection.

MA38591A 2013-05-17 2014-05-16 6-Bridged Heteroaryldihydropyrimidines for the Treatment and Prophylaxis of Hepatitis B Virus Infection MA38591A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013075815 2013-05-17
PCT/EP2014/060034 WO2014184328A1 (en) 2013-05-17 2014-05-16 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection

Publications (1)

Publication Number Publication Date
MA38591A1 true MA38591A1 (en) 2017-08-31

Family

ID=56120455

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38591A MA38591A1 (en) 2013-05-17 2014-05-16 6-Bridged Heteroaryldihydropyrimidines for the Treatment and Prophylaxis of Hepatitis B Virus Infection

Country Status (2)

Country Link
AR (1) AR096333A1 (en)
MA (1) MA38591A1 (en)

Also Published As

Publication number Publication date
AR096333A1 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
MA41338B1 (en) Pyrazine compounds for the treatment of infectious diseases
MA41134A (en) 5-AMINO-6H-THIAZOLO [4,5-D] PYRIMIDINE-2,7-DIONE SUBSTITUTE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRAL INFECTIONS
MA37942A2 (en) 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MA46038B1 (en) Sulfonimidoylpurinone compounds substituted in the 7 position for the treatment and prophylaxis of viral infection
MA37712B1 (en) Macrocyclic inhibitors of flaviviridae virus
MA35132B1 (en) 4-aryl-n-phenyl-1,3,5-triazine-2-amines containing a sulfoximine group
MA42410A (en) OXYSTEROLS AND THEIR METHODS OF USE
MA42295B1 (en) Benzoxazepin oxazolidinone compounds and method for their use
MA37400B1 (en) Heterocyclyl compounds as mek inhibitors
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MA35750B1 (en) 2 ', 4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of vhc rna replication (hepatitis c virus)
MA34896B1 (en) INHIBITORS OF HEPATITIS C VIRUS
MA38315B1 (en) Heterocycle-substituted tetracyclic compounds and methods for their use in the treatment of viral diseases
MA39777A (en) ORGANIC COMPOUNDS OF THE MONOBACTAMS FAMILY FOR THE TREATMENT OF BACTERIAL INFECTIONS
MA40225A (en) SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS
MA33275B1 (en) HIV inhibitors
MA40955A (en) 2-AMINO-6- (DIFLUOROMETHYL) -5,5-DIFLUORO-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS
MA32231B1 (en) Organic compounds
EA201391290A1 (en) HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS
TN2015000347A1 (en) AZABENZIMIDAZOLES AS INHIBITORS OF PDE4 ISOENZYMES FOR THE TREATMENT OF CNS DISORDERS AND OTHER DISORDERS
MA38661A1 (en) Heteroaromatic compounds and their use as d1 dopamine ligands
MA35895B1 (en) Iap inhibitors
MA35104B1 (en) Inhibitor of the hepatitis c virus
MA39170B1 (en) Serine / threonine kinase inhibitory compounds for their uses in the treatment of cancer
MA39165A1 (en) Benzimidazole-proline derivatives for their use in the treatment of crepuscular state syndrome